Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the use of imetelstat, a telomerase inhibitor, as evaluated in a Phase II randomized study investigating its use (NCT02426086). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть